Gennao Bio Presents Preclinical Data Highlighting GMAB’s Ability to Systemically Target and Deliver RNA to Central Nervous System Tumors at the AACR-NCI-EORTC International Conference
~ Studies with fluorescently labeled GMAB demonstrate the antibody readily penetrates the central nervous system and achieves tumor-specific delivery ~
~ Studies combining GMAB with the RIG-I ligand 3p-hpRNA show a significant reduction in tumor burden and prevention of spinal metastases ~
HOPEWELL, N.J.--(BUSINESS WIRE)-- Gennao Bio, a privately-held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical data for its gene monoclonal antibody (GMAB) platform technology was presented as a virtual poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
The results presented demonstrate GMAB’s ability to systemically target and deliver an RNA payload to central nervous system (CNS) tumors in a mouse model of human medulloblastoma (DAOY). Studies conducted with fluorescently labeled GMAB show that the antibody readily penetrates into the central nervous system, and is quickly internalized and retained by tumors. Additional studies combining GMAB with 3p-hpRNA, a known activator of the immune signaling RIG-I pathway, show more than 50% reduction in intracranial tumor burden and suppression of spinal metastases following a single dose.
“The results presented today further reinforce the potential of our GMAB platform in oncology and support continued advancement. We look forward to nominating our first clinical program by the end of the year,” said Stephen Squinto, Ph.D., chief executive officer and chair of the board of Gennao Bio.
“Treating CNS tumors systemically is challenging given the need to cross the blood-brain barrier and often requires the use of complicated formulations and invasive methods of delivery,” said Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine. “These promising results highlight a novel, non-invasive, targeted approach for the systemic delivery of immunostimulatory RNAs to multiple tumors, offering the potential for improved treatments options over current approaches.”
The full abstract and poster presentation can be accessed on the AACR-NCI-EORTC conference website.
About Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Source: Gennao Bio